Exelixis (FRA:EX9) Institutional Ownership: 64.52% (As of Aug. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:EX9 Exelixis Inc FRA:EX9
90 GF Score
Price €46.16
GF Value €40.66
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Exelixis Institutional Ownership?

Exelixis FRA:EX9 +3.50% 90 Institutional Ownership is 64.52% as of Aug. 20, 2026. GuruFocus rates FRA:EX9 with a GF Score™ of 90/100 and a GF Value™ of €40.66 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Exelixis's institutional ownership is 64.52%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Exelixis's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Exelixis's Float Percentage Of Total Shares Outstanding is 73.16%.

Exelixis Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Exelixis's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Exelixis Institutional Ownership Chart

Exelixis Historical Data

The historical data trend for Exelixis can be seen below:

2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 61.98 61.95 62.34 63.48 63.72 63.01 63.02 62.61 63.60 64.52
FRA:EX9
90GF Score
Exelixis Inc FRA:EX9
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Exelixis Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 64.52% mean?
Exelixis (FRA:EX9) has a Institutional Ownership of 64.52% as of Aug. 20, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Exelixis and its competitors.
Is Exelixis' Institutional Ownership too high?
Exelixis' current Institutional Ownership is 64.52%. Overall, Exelixis has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Exelixis' Institutional Ownership compare to MDGL and AXSM?
Exelixis' Institutional Ownership of 64.52% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Exelixis and its competitors. Exelixis's current Institutional Ownership is 64.52%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exelixis stock overvalued right now?
Based on GuruFocus' analysis, Exelixis (FRA:EX9) is currently considered Modestly Overvalued. The stock's GF Value™ is €40.66, compared to a current price of €46.16 — trading 13.5% above its estimated fair value. The current Institutional Ownership is 64.52%. Exelixis' overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Exelixis (FRA:EX9), the current Institutional Ownership is 64.52% as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Exelixis (FRA:EX9) Overvalued in 2026?

Based on GuruFocus' analysis, Exelixis stock appears to be overvalued. The current stock price of €46.16 is trading 13.5% above its estimated GF Value™ of €40.66. GuruFocus considers Exelixis to be Modestly Overvalued.

Key valuation signals for FRA:EX9:

  • Institutional Ownership: 64.52%
  • GF Value™: €40.66 vs. price of €46.16 (13.5% above fair value)
  • GF Score™: 90/100 with 4 warning signs

No single metric tells the full story. See the FRA:EX9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Exelixis Business Description

Address 1851 Harbor Bay Parkway, Alameda, CA, USA, 94502
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
90GF Score

Get the complete analysis for FRA:EX9

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€46.16
Price
€40.66
GF Value